La Jolla Institute for Immunology

What we can learn from SARS

Researchers comb through hundreds of studies to find clues to beating COVID-19
22-May-2020 12:55 PM EDT, by La Jolla Institute for Immunology

Newswise — LA JOLLA, CA—Seventeen years ago, another viral outbreak was in the news. People wore masks, many were nervous to fly. This outbreak, known as SARS, was caused by a type of coronavirus we now call SARS-CoV-1. The difference was that SARS-CoV-1 was controlled and the virus is all but extinct. The newspaper headlines became a distant memory.

But research on coronaviruses continued in labs around the world, and those studies have helped inform the fast-paced COVID-19 research today.

“We need solutions right now,” says Sara Landeras-Bueno, Ph.D., a postdoctoral researcher at La Jolla Institute (LJI). “But it’s so challenging to stay up-to-date on all the publications.”

Indeed, researchers today are publishing 50 to 100 studies a day on COVID-19, and not all the studies have been subject to rigorous peer review. To help researchers understand the mountain of new coronavirus data, Ying-Ting Wang, Ph.D., Sara Landeras-Bueno Ph.D., Jose Angel Regla-Nava, Ph.D., and colleagues recently led a review comparing findings from more than 200 COVID-19 studies with immunological and virological findings in previous SARS research. Their summary, published this week in the online edition of Trends in Microbiology, emphasizes the need for better animal models and structural studies for COVID-19 treatment and vaccine development.

Regla-Nava, who has experience studying SARS and MERS, explains that the viruses that cause SARS and COVID-19 are 79 percent identical. This means we could potentially learn a lot from SARS about how long immunity might last against the novel coronavirus, called SARS-CoV-2. Several recent studies have shown that a person exposed to SARS can still have SARS-fighting antibodies for many years after infection. But the actual number of antibodies really declines after two years.

This could mean that vaccines and natural immunity against SARS-CoV-2 may only provide protection for a few years. 

The researchers also looked at structural studies showing where antibodies can attack these viruses. Both viruses have “spike” proteins that protrude from the virus and are exposed to the human immune system.

Can SARS antibodies also attack these spike proteins on the novel coronavirus? “Although most of the proteins in these viruses are similar, they are not exactly the same,” says Landeras-Bueno. “So it was not easy to find antibodies that could neutralize both.”

Regla-Nava believes we’ll have to tweak current mouse models in the effort to develop vaccines that can elicit truly neutralizing antibodies. “It’s really important to have good animal models for these studies,” he says.

In the meantime, the LJI team is hard at work as part of the LJI Coronavirus Task Force. Wang says it remains critical to try to stay up-to-date with breakthroughs worldwide and summarize those findings in a useful way.

“This is what we can do for now to help the scientific community,” says Wang. 

This review was supported by the Ley, Shresta and Saphire labs at LJI. The work was funded by the Bill and Melinda Gates Foundation grant # INV-006133.

Full citation: Ying-Ting Wang, Sara Landeras-Bueno, Li-En Hsieh, Yutaka Terada, Kenneth Kim, Klaus Ley, Sujan Shresta, Erica Ollmann Saphire and  Jose Angel Regla-Nava. Spiking Pandemic Potential: Structural and Immunological aspects of SARS-CoV-2. Trends in Microbiology, 2020. Doi: https://doi.org/10.1016/j.tim.2020.05.012

Read the review: Spiking Pandemic Potential: Structural and Immunological aspects of SARS-CoV-2

About La Jolla Institute for Immunology

The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

 

 




Filters close

Showing results

110 of 1990
Newswise: Calibrated approach to AI and deep learning models could more reliably diagnose and treat disease
Released: 29-May-2020 6:05 AM EDT
Calibrated approach to AI and deep learning models could more reliably diagnose and treat disease
Lawrence Livermore National Laboratory

In a recent preprint (available through Cornell University’s open access website arXiv), a team led by a Lawrence Livermore National Laboratory computer scientist proposes a novel deep learning approach aimed at improving the reliability of classifier models designed for predicting disease types from diagnostic images, with an additional goal of enabling interpretability by a medical expert without sacrificing accuracy. The approach uses a concept called confidence calibration, which systematically adjusts the model’s predictions to match the human expert’s expectations in the real world.

Newswise: Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique
Released: 28-May-2020 6:35 PM EDT
Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique
University of Maryland Medical Center

Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.

Released: 28-May-2020 6:05 PM EDT
Tackling airborne transmission of COVID-19 indoors
University of Surrey

Preventing airborne transmission of Covid-19 should be the next front of the battle against the virus, argue experts from the University of Surrey.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Jun-2020 11:00 AM EDT Released to reporters: 28-May-2020 5:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 1-Jun-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 28-May-2020 5:10 PM EDT
Mental health outcomes among health care workers during COVID-19 pandemic in Italy
JAMA - Journal of the American Medical Association

Symptoms of posttraumatic stress disorder, depression, anxiety and insomnia among health care workers in Italy during the COVID-19 pandemic are reported in this observational study.

Newswise: fimmu-11-01208-g001.jpg
Released: 28-May-2020 4:45 PM EDT
Genetics May Explain High COVID-19 Mortality in Italy, Inform Global Pandemic Response
Sbarro Health Research Organization (SHRO)

On March 11th 2020 the World Health Organization declared Coronavirus disease (COVID-19) a pandemic.

Released: 28-May-2020 3:55 PM EDT
Finding working capital is key to small businesses efforts as reopening accelerates
RAND Corporation

As small businesses reopen after a lengthy pandemic shutdown, one key challenge will be finding working capital to replenish inventories and pay employees until revenue returns to normal, according to a new RAND Corporation perspective based on interviews with a select group of small business owners.

Newswise: Leading Mindfully: COVID-19 and the Big Human Pivot, Part 3
Released: 28-May-2020 3:15 PM EDT
Leading Mindfully: COVID-19 and the Big Human Pivot, Part 3
University of Virginia Darden School of Business

If the COVID-19 crisis triggered health, economic, social and psychological changes that mean we will be living and working through destabilizing moments now and for the foreseeable future, then all the more reason now to adopt and practice essential skills of Leading Mindfully. How should we start thinking in new ways that better represent reality?

access_time Embargo lifts in 2 days
Embargo will expire: 1-Jun-2020 6:00 AM EDT Released to reporters: 28-May-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 1-Jun-2020 6:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results

110 of 1990

close
1.23128